News on Dynal Biotech ASA from BioPortfolio.com http://www.BioPortfolio.com Consolidated Dynal Biotech ASA news from BioPortfolio.com Wed, 10 Feb 2010 01:17:29 GMT en Clavis Pharma ASA-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033638&HITNO=0&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033638&THISHREF=http://c.moreover.com/click/here.pl%3fz2535298936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033638&HITNO=0&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033638&THISHREF=http://c.moreover.com/click/here.pl%3fz2535298936%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Aker BioMarine (NO) - Aker BioMarine refinancing planhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032854&HITNO=1&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032854&THISHREF=http://c.moreover.com/click/here.pl%3fz2534835865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032854&HITNO=1&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032854&THISHREF=http://c.moreover.com/click/here.pl%3fz2534835865%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Regulations of the key mediators in inflammation and atherosclerosis by Aspirin in human macrophageshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027989&HITNO=2&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027989&THISHREF=http://c.moreover.com/click/here.pl%3fz2532517311%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4027989&HITNO=2&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4027989&THISHREF=http://c.moreover.com/click/here.pl%3fz2532517311%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Will there be a future for us?http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024590&HITNO=3&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024590&THISHREF=http://c.moreover.com/click/here.pl%3fz2528998625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024590&HITNO=3&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024590&THISHREF=http://c.moreover.com/click/here.pl%3fz2528998625%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comExpress Buzz: Algeta announces first patient treated in phase II trial of Alpharadin to treat bone metastases in breast canchttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018107&HITNO=4&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018107&THISHREF=http://c.moreover.com/click/here.pl%3fz2525480247%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4018107&HITNO=4&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4018107&THISHREF=http://c.moreover.com/click/here.pl%3fz2525480247%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBionity.com: Yara acquires remaining 50% of Balderton Fertiliserhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009415&HITNO=5&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009415&THISHREF=http://c.moreover.com/click/here.pl%3fz2521972465%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009415&HITNO=5&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009415&THISHREF=http://c.moreover.com/click/here.pl%3fz2521972465%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comChemie.de: DnB NOR reviews Oslo-listed healthcare, pharmaceutical stockshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005736&HITNO=6&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005736&THISHREF=http://c.moreover.com/click/here.pl%3fz2520456830%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005736&HITNO=6&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005736&THISHREF=http://c.moreover.com/click/here.pl%3fz2520456830%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comADP News: California medical team touches down in Haitihttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996437&HITNO=7&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996437&THISHREF=http://c.moreover.com/click/here.pl%3fz2516297028%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996437&HITNO=7&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996437&THISHREF=http://c.moreover.com/click/here.pl%3fz2516297028%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEureka Times-Standard: Algeta ASA (NO) - Algeta Announces First Patient Treated in Phase II Trial of Alpharadin to Treat Bone Metastahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999172&HITNO=8&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999172&THISHREF=http://c.moreover.com/click/here.pl%3fz2517346571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999172&HITNO=8&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999172&THISHREF=http://c.moreover.com/click/here.pl%3fz2517346571%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Algeta announces first patient treated in phase II trial of Alpharadin to treat bone metastases in breast canchttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999977&HITNO=9&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999977&THISHREF=http://c.moreover.com/click/here.pl%3fz2517759803%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999977&HITNO=9&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999977&THISHREF=http://c.moreover.com/click/here.pl%3fz2517759803%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Norwegian Algeta starts Alpharadin study in breast cancer - Zibb....http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999708&HITNO=10&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999708&THISHREF=http://c.moreover.com/click/here.pl%3fz2517599785%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999708&HITNO=10&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999708&THISHREF=http://c.moreover.com/click/here.pl%3fz2517599785%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Norwegian Algeta starts Alpharadin study in breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999666&HITNO=11&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999666&THISHREF=http://c.moreover.com/click/here.pl%3fz2517582956%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999666&HITNO=11&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999666&THISHREF=http://c.moreover.com/click/here.pl%3fz2517582956%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Norwegian Algeta starts Alpharadin study in breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999659&HITNO=12&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999659&THISHREF=http://c.moreover.com/click/here.pl%3fz2517579801%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999659&HITNO=12&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999659&THISHREF=http://c.moreover.com/click/here.pl%3fz2517579801%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Norwegian Algeta starts Alpharadin study in breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999531&HITNO=13&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999531&THISHREF=http://c.moreover.com/click/here.pl%3fz2517479373%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999531&HITNO=13&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999531&THISHREF=http://c.moreover.com/click/here.pl%3fz2517479373%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comM2: Algeta announces first patient treated in phase II trial of Alpharadin to treat bone metastases in breast canchttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995441&HITNO=14&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995441&THISHREF=http://c.moreover.com/click/here.pl%3fz2515662833%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995441&HITNO=14&MSIZE=156&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Dynal%20Biotech%20ASA&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995441&THISHREF=http://c.moreover.com/click/here.pl%3fz2515662833%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: